Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00266526

Enrollment

Unknown

Registered

2005-12-19

Start date

2003-07-31

Completion date

2005-07-31

Last updated

2013-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birch Pollen Allergy

Keywords

Allergy, Birch pollen, Recombinant

Brief summary

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Interventions

BIOLOGICALRecombinant birch pollen

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Positive RAST result to birch pollen * Positive Skin Prick Test reaction to birch pollen * positive nasal provocation test result to birch pollen extract

Exclusion criteria

* serious chronic diseases * other relevant seasonal allergies

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026